Peritonitis Treatments

Find Peritonitis Treatments

Peritonitis is a serious medical condition characterized by inflammation of the thin layer of tissue that lines the inside of the abdomen. For patients, the experience is often defined by severe abdominal pain, tenderness, and a rigid, swollen belly that makes movement agonizing. This condition frequently requires hospitalization, which can be sudden and frightening for both the patient and their loved ones. Whether caused by liver disease or a rupture in an abdominal organ, the symptoms demand immediate attention to prevent life-threatening complications.

Treatment is critical to halt the spread of infection throughout the body, a state known as sepsis. The primary goal is to eliminate the bacteria or fungus causing the inflammation and to stabilize the body’s vital functions. Because peritonitis can arise from different causes such as Spontaneous Bacterial Peritonitis (SBP) in liver patients or secondary peritonitis from a burst appendix, treatment plans are tailored to the specific source of the infection and the patient’s overall health stability (Mayo Clinic, 2023).

Overview of treatment options for Peritonitis

The management of peritonitis is aggressive and almost always begins in a hospital setting. The immediate priorities are to fight the infection and manage severe pain. Pharmacological treatment is the cornerstone of care, often starting intravenously (IV) to ensure rapid delivery of medication into the bloodstream.

For cases of secondary peritonitis (caused by a rupture), surgery is typically required to repair the underlying issue, but medications are essential before and after the procedure to control the infection. For SBP, medication is usually the primary treatment without the need for surgery. Clinical experience suggests that the prompt administration of broad-spectrum antibiotics, even before the specific bacteria is identified, is crucial for positive outcomes.

Medications used for Peritonitis

Antibiotics are the first-line defense for bacterial peritonitis. Initially, doctors prescribe “empiric” therapy, which involves broad-spectrum antibiotics capable of fighting a wide range of bacteria. Once lab results identify the specific organism, the medication may be adjusted.

  • Cephalosporins: Third-generation cephalosporins, such as cefotaxime or ceftriaxone, are frequently the drug of choice, particularly for spontaneous bacterial peritonitis. They are effective against common gram-negative bacteria.
  • Penicillins combined with Beta-Lactamase Inhibitors: Drugs like piperacillin-tazobactam are often used for more complex or severe infections to overcome bacterial resistance.
  • Carbapenems: In cases of severe hospital-acquired infections or multi-drug resistance, potent antibiotics like meropenem may be utilized.

If the infection is caused by a fungus (Candida), which is less common but possible in patients on peritoneal dialysis or with perforated ulcers, antifungal medications are prescribed.

  • Antifungals: Fluconazole or echinocandins (like micafungin) are standard options to target fungal overgrowth.

Pain management is also a critical component of medication therapy.

  • Analgesics: Due to the severity of the pain, doctors may prescribe opioid analgesics (such as morphine or hydromorphone) to keep the patient comfortable.

Patients typically receive antibiotics via IV for several days before switching to oral medications as they recover. Improvement in fever and pain is often seen within 48 to 72 hours of starting effective therapy (National Institute of Diabetes and Digestive and Kidney Diseases, 2021).

How these medications work

Antibiotics fight infection by disrupting bacterial vital processes. Classes like cephalosporins and penicillins destroy the bacterial cell wall, causing rupture and death. Others hinder protein production, stopping growth and replication. By reducing abdominal bacterial load, they halt toxin production that causes inflammation and shock.

Antifungals similarly target fungal cell structures, like their distinct cell membranes. Analgesics block pain signals in the central nervous system, promoting essential rest and healing (MedlinePlus, 2022).

Side effects and safety considerations

Strong antibiotics/antifungals often cause nausea, diarrhea, and stomach upset, plus the risk of severe C. difficile infection. High doses or long-term use can damage the kidneys and liver, necessitating strict blood test monitoring of organ function, especially in patients with existing liver disease.

Opioid pain medications cause sedation, dizziness, and constipation, requiring close monitoring of breathing and bowel function. Patients must seek immediate medical attention if symptoms return or if they show signs of an allergic reaction (e.g., rash, swelling).

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care.

References

  1. Mayo Clinic. https://www.mayoclinic.org
  2. MedlinePlus. https://medlineplus.gov
  3. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov
  4. Merck Manuals. https://www.merckmanuals.com

Medications for Peritonitis

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Peritonitis.

Found 9 Approved Drugs for Peritonitis

Ceftazidime

Brand Names
Avycaz, Tazicef

Ceftazidime

Brand Names
Avycaz, Tazicef
AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients aged 3 months and older: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole.

Clindamycin

Brand Names
Acanya, Altreno, Atralin, Cleocin, ClindaCare, Clindacin, Clindacin ETZ, Clindagel, Clindamycin Phoaphate, Clindesse, Neuac, Onexton, Renova, Retin-A, Tretinoin, Tri-Luma, Twyneo, Xaciato, ZIANA

Clindamycin

Brand Names
Acanya, Altreno, Atralin, Cleocin, ClindaCare, Clindacin, Clindacin ETZ, Clindagel, Clindamycin Phoaphate, Clindesse, Neuac, Onexton, Renova, Retin-A, Tretinoin, Tri-Luma, Twyneo, Xaciato, ZIANA
ACANYA ® Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. ACANYA Gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of acne vulgaris in patients 12 years or older. ( 1 )

Diflucan

Generic Name
Fluconazole

Diflucan

Generic Name
Fluconazole
DIFLUCAN (fluconazole) is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, DIFLUCAN was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing DIFLUCAN (fluconazole) for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing DIFLUCAN to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis: DIFLUCAN is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly.

Arikayce

Generic Name
Amikacin

Arikayce

Generic Name
Amikacin
LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. LIMITED POPULATION: ARIKAYCE is an aminoglycoside antibacterial indicated in adults who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients. ( 1 ) This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. ( 1 ) Limitation of Use: ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease. Limitation of Use : ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Tobramycin

Brand Names
Bethkis, TOBI, TOBI Podhaler, TobraDex, Tobrex

Tobramycin

Brand Names
Bethkis, TOBI, TOBI Podhaler, TobraDex, Tobrex
BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia. BETHKIS is an inhaled aminoglycoside antibacterial indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa. ( 1 ) Safety and efficacy have not been demonstrated in patients under the age of six years, patients with a forced expiratory volume in one second (FEV 1 ) less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia. ( 1 )
Showing 1-5 of 9
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances